[1]
Scipione CA, Koschinsky ML, Boffa MB. Lipoprotein(a) in clinical practice: New perspectives from basic and translational science. Critical reviews in clinical laboratory sciences. 2018 Jan:55(1):33-54. doi: 10.1080/10408363.2017.1415866. Epub 2017 Dec 20
[PubMed PMID: 29262744]
Level 3 (low-level) evidence
[2]
Maranhão RC, Carvalho PO, Strunz CC, Pileggi F. Lipoprotein (a): structure, pathophysiology and clinical implications. Arquivos brasileiros de cardiologia. 2014 Jul:103(1):76-84
[PubMed PMID: 25120086]
[3]
Yamauchi K. [Electrophoretic Analysis of Serum Lipoproteins: Its Usefulness and Problems]. Rinsho byori. The Japanese journal of clinical pathology. 2014 Nov:62(11):1079-87
[PubMed PMID: 27509725]
[4]
Rader DJ, Cain W, Ikewaki K, Talley G, Zech LA, Usher D, Brewer HB Jr. The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate. The Journal of clinical investigation. 1994 Jun:93(6):2758-63
[PubMed PMID: 8201014]
[5]
Enas EA, Varkey B, Dharmarajan TS, Pare G, Bahl VK. Lipoprotein(a): An independent, genetic, and causal factor for cardiovascular disease and acute myocardial infarction. Indian heart journal. 2019 Mar-Apr:71(2):99-112. doi: 10.1016/j.ihj.2019.03.004. Epub 2019 Mar 20
[PubMed PMID: 31280836]
[6]
Nordestgaard BG, Chapman MJ, Ray K, Borén J, Andreotti F, Watts GF, Ginsberg H, Amarenco P, Catapano A, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Reiner Z, Taskinen MR, Tokgözoglu L, Tybjærg-Hansen A, European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status. European heart journal. 2010 Dec:31(23):2844-53. doi: 10.1093/eurheartj/ehq386. Epub 2010 Oct 21
[PubMed PMID: 20965889]
[7]
Kotani K, Banach M. Lipoprotein(a) and inhibitors of proprotein convertase subtilisin/kexin type 9. Journal of thoracic disease. 2017 Jan:9(1):E78-E82. doi: 10.21037/jtd.2017.01.40. Epub
[PubMed PMID: 28203441]
[8]
Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. The Journal of clinical investigation. 1992 Jul:90(1):52-60
[PubMed PMID: 1386087]
[9]
Klausen IC, Sjøl A, Hansen PS, Gerdes LU, Møller L, Lemming L, Schroll M, Faergeman O. Apolipoprotein(a) isoforms and coronary heart disease in men: a nested case-control study. Atherosclerosis. 1997 Jul 11:132(1):77-84
[PubMed PMID: 9247362]
Level 2 (mid-level) evidence
[10]
Romagnuolo R, Marcovina SM, Boffa MB, Koschinsky ML. Inhibition of plasminogen activation by apo(a): role of carboxyl-terminal lysines and identification of inhibitory domains in apo(a). Journal of lipid research. 2014 Apr:55(4):625-34. doi: 10.1194/jlr.M036566. Epub 2014 Jan 29
[PubMed PMID: 24478033]
[11]
Sandmark J, Tigerström A, Akerud T, Althage M, Antonsson T, Blaho S, Bodin C, Boström J, Chen Y, Dahlén A, Eriksson PO, Evertsson E, Fex T, Fjellström O, Gustafsson D, Herslöf M, Hicks R, Jarkvist E, Johansson C, Kalies I, Karlsson Svalstedt B, Kartberg F, Legnehed A, Martinsson S, Moberg A, Ridderström M, Rosengren B, Sabirsh A, Thelin A, Vinblad J, Wellner AU, Xu B, Östlund-Lindqvist AM, Knecht W. Identification and analyses of inhibitors targeting apolipoprotein(a) kringle domains KIV-7, KIV-10, and KV provide insight into kringle domain function. The Journal of biological chemistry. 2020 Apr 10:295(15):5136-5151. doi: 10.1074/jbc.RA119.011251. Epub 2020 Mar 4
[PubMed PMID: 32132173]
[12]
Chan DC, Watts GF, Coll B, Wasserman SM, Marcovina SM, Barrett PHR. Lipoprotein(a) Particle Production as a Determinant of Plasma Lipoprotein(a) Concentration Across Varying Apolipoprotein(a) Isoform Sizes and Background Cholesterol-Lowering Therapy. Journal of the American Heart Association. 2019 Apr 2:8(7):e011781. doi: 10.1161/JAHA.118.011781. Epub
[PubMed PMID: 30897995]
[13]
Reyes-Soffer G, Ginsberg HN, Berglund L, Duell PB, Heffron SP, Kamstrup PR, Lloyd-Jones DM, Marcovina SM, Yeang C, Koschinsky ML, American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Radiology and Intervention; and Council on Peripheral Vascular Disease. Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association. Arteriosclerosis, thrombosis, and vascular biology. 2022 Jan:42(1):e48-e60. doi: 10.1161/ATV.0000000000000147. Epub 2021 Oct 14
[PubMed PMID: 34647487]
[14]
Cook-Mills JM, Marchese ME, Abdala-Valencia H. Vascular cell adhesion molecule-1 expression and signaling during disease: regulation by reactive oxygen species and antioxidants. Antioxidants & redox signaling. 2011 Sep 15:15(6):1607-38. doi: 10.1089/ars.2010.3522. Epub 2011 May 11
[PubMed PMID: 21050132]
[15]
Lu Y, Cui X, Zhang L, Wang X, Xu Y, Qin Z, Liu G, Wang Q, Tian K, Lim KS, Charles CJ, Zhang J, Tang J. The Functional Role of Lipoproteins in Atherosclerosis: Novel Directions for Diagnosis and Targeting Therapy. Aging and disease. 2022 Apr:13(2):491-520. doi: 10.14336/AD.2021.0929. Epub 2022 Apr 1
[PubMed PMID: 35371605]
Level 2 (mid-level) evidence
[16]
Anglés-Cano E, de la Peña Díaz A, Loyau S. Inhibition of fibrinolysis by lipoprotein(a). Annals of the New York Academy of Sciences. 2001:936():261-75
[PubMed PMID: 11460483]
[17]
Ugovšek S, Šebeštjen M. Lipoprotein(a)-The Crossroads of Atherosclerosis, Atherothrombosis and Inflammation. Biomolecules. 2021 Dec 24:12(1):. doi: 10.3390/biom12010026. Epub 2021 Dec 24
[PubMed PMID: 35053174]
[18]
Orsó E, Schmitz G. Lipoprotein(a) and its role in inflammation, atherosclerosis and malignancies. Clinical research in cardiology supplements. 2017 Mar:12(Suppl 1):31-37. doi: 10.1007/s11789-017-0084-1. Epub
[PubMed PMID: 28188431]
[19]
Nordestgaard BG, Langsted A, Mora S, Kolovou G, Baum H, Bruckert E, Watts GF, Sypniewska G, Wiklund O, Borén J, Chapman MJ, Cobbaert C, Descamps OS, von Eckardstein A, Kamstrup PR, Pulkki K, Kronenberg F, Remaley AT, Rifai N, Ros E, Langlois M, European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) joint consensus initiative. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. European heart journal. 2016 Jul 1:37(25):1944-58. doi: 10.1093/eurheartj/ehw152. Epub 2016 Apr 26
[PubMed PMID: 27122601]
Level 3 (low-level) evidence
[20]
Nikolac N. Lipemia: causes, interference mechanisms, detection and management. Biochemia medica. 2014:24(1):57-67. doi: 10.11613/BM.2014.008. Epub 2014 Feb 15
[PubMed PMID: 24627715]
[21]
Wilson DP, Jacobson TA, Jones PH, Koschinsky ML, McNeal CJ, Nordestgaard BG, Orringer CE. Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. Journal of clinical lipidology. 2019 May-Jun:13(3):374-392. doi: 10.1016/j.jacl.2019.04.010. Epub 2019 May 17
[PubMed PMID: 31147269]
[22]
Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC Jr, Sperling L, Virani SS, Yeboah J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019 Jun 18:139(25):e1046-e1081. doi: 10.1161/CIR.0000000000000624. Epub 2018 Nov 10
[PubMed PMID: 30565953]
Level 1 (high-level) evidence
[23]
Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O, ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European heart journal. 2020 Jan 1:41(1):111-188. doi: 10.1093/eurheartj/ehz455. Epub
[PubMed PMID: 31504418]
[24]
Marcovina SM, Albers JJ. Lipoprotein (a) measurements for clinical application. Journal of lipid research. 2016 Apr:57(4):526-37. doi: 10.1194/jlr.R061648. Epub 2015 Dec 4
[PubMed PMID: 26637278]
[25]
Marcovina SM, Navabi N, Allen S, Gonen A, Witztum JL, Tsimikas S. Development and validation of an isoform-independent monoclonal antibody-based ELISA for measurement of lipoprotein(a). Journal of lipid research. 2022 Aug:63(8):100239. doi: 10.1016/j.jlr.2022.100239. Epub 2022 Jun 8
[PubMed PMID: 35688187]
Level 1 (high-level) evidence
[26]
Kostner KM, März W, Kostner GM. When should we measure lipoprotein (a)? European heart journal. 2013 Nov:34(42):3268-76. doi: 10.1093/eurheartj/eht053. Epub 2013 Jun 4
[PubMed PMID: 23735860]
[27]
Herzum I, Giehl C, Soufi M, Junclas H, Wahl HG. Interference in a homogeneous assay for low-density lipoprotein cholesterol by lipoprotein X. Clinical chemistry and laboratory medicine. 2007:45(5):667-71
[PubMed PMID: 17484632]
[28]
Cegla J, France M, Marcovina SM, Neely RDG. Lp(a): When and how to measure it. Annals of clinical biochemistry. 2021 Jan:58(1):16-21. doi: 10.1177/0004563220968473. Epub 2020 Oct 28
[PubMed PMID: 33040574]
[29]
Nissen SE, Wolski K, Cho L, Nicholls SJ, Kastelein J, Leitersdorf E, Landmesser U, Blaha M, Lincoff AM, Morishita R, Tsimikas S, Liu J, Manning B, Kozlovski P, Lesogor A, Thuren T, Shibasaki T, Matei F, Silveira FS, Meunch A, Bada A, Vijan V, Bruun NE, Nordestgaard BG, Lp(a)HERITAGE Investigators. Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease. Open heart. 2022 Oct:9(2):. doi: 10.1136/openhrt-2022-002060. Epub
[PubMed PMID: 36252994]
[30]
Ćwiklińska A, Mickiewicz A, Kowalski R, Kortas-Stempak B, Kuchta A, Mucha K, Makowiecki M, Gliwińska A, Lewandowski K, Pączek L, Fijałkowski M, Gruchała M, Jankowski M. Detection of Lipoprotein X (LpX): A challenge in patients with severe hypercholesterolaemia. Journal of medical biochemistry. 2020 Sep 2:39(3):283-289. doi: 10.2478/jomb-2019-0038. Epub
[PubMed PMID: 33269016]
[31]
Chakraborty A, Chan DC, Ellis KL, Pang J, Barnett W, Woodward AM, Vorster M, Norman R, Moses EK, Watts GF. Cascade testing for elevated lipoprotein(a) in relatives of probands with high lipoprotein(a). American journal of preventive cardiology. 2022 Jun:10():100343. doi: 10.1016/j.ajpc.2022.100343. Epub 2022 Apr 21
[PubMed PMID: 35517871]
[32]
Saeedi R, Frohlich J. Lipoprotein (a), an independent cardiovascular risk marker. Clinical diabetes and endocrinology. 2016:2():7. doi: 10.1186/s40842-016-0024-x. Epub 2016 Mar 31
[PubMed PMID: 28702242]
[33]
Boden WE, Sidhu MS, Toth PP. The therapeutic role of niacin in dyslipidemia management. Journal of cardiovascular pharmacology and therapeutics. 2014 Mar:19(2):141-58. doi: 10.1177/1074248413514481. Epub 2013 Dec 20
[PubMed PMID: 24363242]
[34]
Tsimikas S, Gordts PLSM, Nora C, Yeang C, Witztum JL. Statin therapy increases lipoprotein(a) levels. European heart journal. 2020 Jun 21:41(24):2275-2284. doi: 10.1093/eurheartj/ehz310. Epub
[PubMed PMID: 31111151]
[35]
Navarese EP, Kolodziejczak M, Schulze V, Gurbel PA, Tantry U, Lin Y, Brockmeyer M, Kandzari DE, Kubica JM, D'Agostino RB Sr, Kubica J, Volpe M, Agewall S, Kereiakes DJ, Kelm M. Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis. Annals of internal medicine. 2015 Jul 7:163(1):40-51. doi: 10.7326/M14-2957. Epub
[PubMed PMID: 25915661]
Level 1 (high-level) evidence
[36]
Harman SM, Vittinghoff E, Brinton EA, Budoff MJ, Cedars MI, Lobo RA, Merriam GR, Miller VM, Naftolin F, Pal L, Santoro N, Taylor HS, Black DM. Timing and duration of menopausal hormone treatment may affect cardiovascular outcomes. The American journal of medicine. 2011 Mar:124(3):199-205. doi: 10.1016/j.amjmed.2010.09.021. Epub
[PubMed PMID: 21396500]
[37]
Zmunda JM, Thompson PD, Dickenson R, Bausserman LL. Testosterone decreases lipoprotein(a) in men. The American journal of cardiology. 1996 Jun 1:77(14):1244-7
[PubMed PMID: 8651107]
[38]
Samulak JJ, Sawicka AK, Hartmane D, Grinberga S, Pugovics O, Lysiak-Szydlowska W, Olek RA. L-Carnitine Supplementation Increases Trimethylamine-N-Oxide but not Markers of Atherosclerosis in Healthy Aged Women. Annals of nutrition & metabolism. 2019:74(1):11-17. doi: 10.1159/000495037. Epub 2018 Nov 28
[PubMed PMID: 30485835]
[39]
Serban MC, Sahebkar A, Mikhailidis DP, Toth PP, Jones SR, Muntner P, Blaha MJ, Andrica F, Martin SS, Borza C, Lip GY, Ray KK, Rysz J, Hazen SL, Banach M. Impact of L-carnitine on plasma lipoprotein(a) concentrations: A systematic review and meta-analysis of randomized controlled trials. Scientific reports. 2016 Jan 12:6():19188. doi: 10.1038/srep19188. Epub 2016 Jan 12
[PubMed PMID: 26754058]
Level 1 (high-level) evidence
[40]
Nurmohamed NS, Kraaijenhof JM, Stroes ESG. Lp(a): a New Pathway to Target? Current atherosclerosis reports. 2022 Nov:24(11):831-838. doi: 10.1007/s11883-022-01060-4. Epub 2022 Sep 6
[PubMed PMID: 36066785]
[41]
Enkhmaa B, Petersen KS, Kris-Etherton PM, Berglund L. Diet and Lp(a): Does Dietary Change Modify Residual Cardiovascular Risk Conferred by Lp(a)? Nutrients. 2020 Jul 7:12(7):. doi: 10.3390/nu12072024. Epub 2020 Jul 7
[PubMed PMID: 32646066]
[42]
Sahebkar A, Katsiki N, Ward N, Reiner Ž. Flaxseed Supplementation Reduces Plasma Lipoprotein(a) Levels: A Meta-Analysis. Alternative therapies in health and medicine. 2021 May:27(3):50-53
[PubMed PMID: 31634874]
Level 1 (high-level) evidence
[43]
Mackinnon LT, Hubinger LM. Effects of exercise on lipoprotein(a). Sports medicine (Auckland, N.Z.). 1999 Jul:28(1):11-24
[PubMed PMID: 10461709]
[44]
Plebani M. Errors in clinical laboratories or errors in laboratory medicine? Clinical chemistry and laboratory medicine. 2006:44(6):750-9
[PubMed PMID: 16729864]
[45]
Allen LC. Role of a quality management system in improving patient safety - laboratory aspects. Clinical biochemistry. 2013 Sep:46(13-14):1187-93. doi: 10.1016/j.clinbiochem.2013.04.028. Epub 2013 May 3
[PubMed PMID: 23648455]
Level 2 (mid-level) evidence
[46]
Ricós C, Fernandez-Calle P, Perich C, Westgard JO. Internal quality control - past, present and future trends. Advances in laboratory medicine. 2022 Oct:3(3):243-262. doi: 10.1515/almed-2022-0029. Epub 2022 May 23
[PubMed PMID: 37362142]
Level 2 (mid-level) evidence
[47]
Ezzelle J, Rodriguez-Chavez IR, Darden JM, Stirewalt M, Kunwar N, Hitchcock R, Walter T, D'Souza MP. Guidelines on good clinical laboratory practice: bridging operations between research and clinical research laboratories. Journal of pharmaceutical and biomedical analysis. 2008 Jan 7:46(1):18-29
[PubMed PMID: 18037599]
[48]
Nichols JH. Laboratory quality control based on risk management. Annals of Saudi medicine. 2011 May-Jun:31(3):223-8. doi: 10.4103/0256-4947.81526. Epub
[PubMed PMID: 21623049]
Level 2 (mid-level) evidence
[49]
Carter JY. External quality assessment in resource-limited countries. Biochemia medica. 2017 Feb 15:27(1):97-109. doi: 10.11613/BM.2017.013. Epub
[PubMed PMID: 28392732]
Level 2 (mid-level) evidence
[50]
James D, Ames D, Lopez B, Still R, Simpson W, Twomey P. External quality assessment: best practice. Journal of clinical pathology. 2014 Aug:67(8):651-5. doi: 10.1136/jclinpath-2013-201621. Epub 2014 Mar 12
[PubMed PMID: 24621574]
Level 2 (mid-level) evidence
[51]
Lock RJ. My approach to internal quality control in a clinical immunology laboratory. Journal of clinical pathology. 2006 Jul:59(7):681-4
[PubMed PMID: 16803947]
Level 2 (mid-level) evidence
[52]
Meisenhelder J, Bursik S, Lunn G, Strober W. Laboratory safety. Current protocols in human genetics. 2008 Apr:Appendix 2():Appendix 2A. doi: 10.1002/0471142905.hga02as57. Epub
[PubMed PMID: 18428418]
[53]
Lo J. Biological safety in the medical laboratory. Hong Kong medical journal = Xianggang yi xue za zhi. 2015 Jun:21(3):200. doi: 10.12809/hkmj154581. Epub
[PubMed PMID: 26045068]
[54]
Drury P. Health and safety in the medical laboratory. Canadian journal of medical technology. 1988 Aug:50(3):177-81
[PubMed PMID: 10289978]